Ask AI
ProCE Banner Activity

Expert Insights on Real-world Cases of TKI Therapy for Patients With CP-CML

Clinical Thought

Gain expert perspectives on the management of clinical challenges with TKIs in patients with chronic-phase CML, including the role of TKI therapy in the frontline setting, when  low-dose TKIs might be applicable, and expert’s thoughts on patients eligible for treatment-free remission and their recommended monitoring strategies in those patients.

Released: December 26, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Target Audience

This educational activity is intended for hematologists, medical oncologists, and other healthcare professionals who care for patients with chronic-phase chronic myeloid leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate important defining characteristics between TKIs and how these attributes influence efficacy and safety outcomes in chronic-phase CML

  • Implement individualized strategies for frontline treatment of chronic-phase CML based on clinical trial evidence, patient-specific factors, and BCR::ABL1 mutation status 

  • Conduct optimal molecular and mutational monitoring during TKI treatment to guide the timing of therapy changes and subsequent therapy decisions in patients with chronic-phase CML 

  • Select optimal subsequent therapy for patients with CP-CML who progress on or become intolerant to frontline TKI treatment

Disclosure

Primary Author

Jerald Radich, MD: consultant/advisor/speaker: Azurity, Enliven, Novartis, ThermoFisher.

Neil P. Shah, MD, PhD: researcher: Kumquat Biosciences; other financial or material support: Novartis.

B. Douglas Smith, MD: consultant/advisor/speaker: Azurity, Enliven, Servier, Takeda.